Northern Exposure PR

We are the leading public relations company serving the life science, pharmaceutical and technology industries.

Northern Exposure is the leading public relations company serving the life science, pharmaceutical and technology industries.

Twenty years experience maximising clients’ media exposure and advising on subjects from press handling, marketing strategy and reputation management

Northern Exposure Public Relations  is uniquely skilled in assisting clients in all public relations requirements

Meet Our Team

hac

Richard Kerns

Richard Kerns

Managing Director

Richard has twenty five years’ experience working with life science companies and organisations around the globe, both independently and within larger agencies.

Edward Dutton

Edward Dutton

Vice President

Ed has over fifteen years experience of working within the pharmaceutical industry, both as a laboratory chemist and in sales and marketing roles within contract research organisations, contract manufacturers and technology based companies.

Sarah Houlton

Sarah Houlton

Technical Consultant in Residence

Sarah has a degree and PhD in chemistry from Imperial College London, and worked as a drug discovery chemist in the pharmaceutical industry. As a science journalist, she has been writing about the pharmaceutical, biotech and chemical industries for more than twenty years.

Our Services

NEPR can assist clients in numerous manners, either on a retained agency basis or through project work around events. Activities include:

Planning & research, web content creation, media relations, technical articles, thought leadership articles, trade show and event management and support, social media, product launches, crisis management & more. 

Contact us today to find out how we can assist you

Our Clients

Client News

20/06/2017 South West Water Switches to Colilert®-18 for all Compliance Testing

09/07/2017 SGS Expands and Increases Capacity by 50% at its Lincolnshire, IL Facility

12/07/2017 Pfizer Partners with Catalent for the Manufacture of Advil® Liqui-Gels® Minis

17/07/2017 Catalent Launches New OptiForm® Solution Suite to Offer Quick and Efficient Path from Late-Stage Discovery to Phase I Clinical Trials

08/08/2017 Cambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity at its Charles City, Iowa Facility

05/09/2017 Catalent Signs Commercial Manufacturing Agreement with US WorldMeds for Lofexidine

05/09/2017 SGS Clinical Research Strengthens its Consultancy Service to Accelerate Drugs Through Early Phase Development

14/09/2017 Catalent Invests $5.5 Million to Increase Clinical Storage Capacity at its Philadelphia Site

19/09/2017 Catalent to Acquire Cook Pharmica for $950 Million

26/09/2017 Cambrex Opens Large Scale API Manufacturing Facility and Invests in Supporting Waste Water Treatment Plant at its Karlskoga, Sweden Site

26/09/2017 SGS Partners with Nature’s Fingerprint to Beat Pharmaceutical Counterfeiting

02/10/2017 Symbiomix Therapeutics Receives FDA Approval of Solosec™ (secnidazole) Oral Granules Following Four-Year Collaboration with Catalent

12/10/2017 SGS and Bavarian Nordic to Develop a Novel and Differentiated Challenge Model for Respiratory Syncytial Virus

12/10/2017 Cambrex Invests in Generic API Development and Manufacturing Capabilities at its Milan Site

23/10/2017 Cambrex Adds Large Scale Manufacturing Capacity at its Charles City, Iowa Facility

24/10/2017 Catalent Completes Acquisition of Cook Pharmica

30/10/2017 Catalent Collaborates with Grid Therapeutics to Develop a Novel Targeted Immuno-Oncology Therapy

08/11/2017 Cambrex Invests in New Small Scale Capacity at its Charles City, Iowa Facility

09/11/2017 Cambrex Wins API Development Award at CPhI Worldwide for Second Consecutive Year

Upcoming Events

NEPR will be attending the following events:

No further events planned in 2017

We are proud to be a shirt sponsor of @swinton_lions for 2018 and be associated with the great club for another year https://t.co/jjbBshr6qT
about 4 weeks ago | @NrthnExposurePR